Goldman Sachs’s Jazz Pharmaceuticals JAZZ Stock Holding History

Goldman Sachs’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-115,000	Closed	-$18.9M	–	6364
2021 Q1	$18.9M	Buy	+115,000	New	+$18.9M	﹤0.01%	1981
2017 Q3	–	Sell	-85,000	Closed	-$13.2M	–	6756
2017 Q2	$13.2M	Buy	+85,000	New	+$13M	﹤0.01%	2290
2017 Q1	–	Sell	-7,200	Closed	-$785K	–	6887
2016 Q4	$785K	Sell	7,200 -5,400	-43%	-$601K	﹤0.01%	4660
2016 Q3	$1.53M	Hold	12,600	–	–	﹤0.01%	4038
2016 Q2	$1.78M	Buy	+12,600	New	+$1.86M	﹤0.01%	3720
2016 Q1	–	Sell	-7,500	Closed	-$1.05M	–	7196
2015 Q4	$1.05M	Hold	7,500	–	–	﹤0.01%	4240
2015 Q3	$996K	Buy	+7,500	New	+$1.29M	﹤0.01%	4490
2015 Q2	–	Sell	-28,700	Closed	-$4.96M	–	7344
2015 Q1	$4.96M	Buy	28,700 +26,200	+1,048%	+$4.5M	﹤0.01%	2914
2014 Q4	$409K	Hold	2,500	–	–	﹤0.01%	5480
2014 Q3	$401K	Sell	2,500 -184,000	-99%	-$28.3M	﹤0.01%	5473
2014 Q2	$27.4M	Buy	186,500 +137,400	+280%	+$19.1M	0.01%	1551
2014 Q1	$6.81M	Sell	49,100 -62,800	-56%	-$9.45M	﹤0.01%	2710
2013 Q4	$14.2M	Buy	+111,900	New	+$11.6M	﹤0.01%	2041

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Goldman Sachs's JAZZ Position: Q1 2026 in Review

Goldman Sachs increased its Jazz Pharmaceuticals (JAZZ) stake by 43% in Q1 2026, buying an estimated $13.3M and bringing the position to 250,321 shares worth $47.3M. The position accounts for 0.01% of the portfolio, ranked #1616.

Goldman Sachs first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $167M in Q4 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Goldman Sachs held 250,321 shares of Jazz Pharmaceuticals worth $47.3M as of Q1 2026.
Goldman Sachs bought 75,844 Jazz Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
Jazz Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1616 holding.
Goldman Sachs first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Jazz Pharmaceuticals position peaked at $167M in Q4 2021.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.